Loading...
•
Mar 31, 2024
Regulus Therapeutics Q1 2024 Earnings Report
Regulus Therapeutics reported financial results for Q1 2024 and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported a net loss of $8.5 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $107.7 million as of March 31, 2024, providing a cash runway into H1 2026. The company is advancing its RGLS8429 program for ADPKD, with topline data from the third cohort of the Phase 1b MAD study expected in mid-2024.
Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 is expected in mid-2024.
Ended first quarter 2024 with cash, cash equivalents, and investments of $107.7 million, providing a cash runway into H1 2026.
Closed an oversubscribed $100 million private placement in March 2024.
Regulus Therapeutics
Regulus Therapeutics
Forward Guidance
The company expects topline data from the third cohort of the Phase 1b MAD study of RGLS8429 in mid-2024 and anticipates its cash runway to extend into H1 2026.